# EV-301 (NCT03474107)

> A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03474107
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Ureteral Cancer; Urothelial Cancer; Bladder Cancer
- Interventions: Enfortumab Vedotin; Docetaxel; Vinflunine; Paclitaxel
- Enrollment: 608
- Primary outcome: Overall Survival (OS)

## Questions raised in the commentary

_Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice._

Discussion covers post-hoc analyses of enfortumab vedotin exposure and dose modification, including the relationship between early exposure, response, and subsequent dose reductions or holds. It considers whether starting-dose intensity and later changes in exposure may influence outcomes, and examines dose-related analyses in EV-301. Commentary also addresses health-related quality-of-life domains, including pain, appetite, and neuropathy, and raises the need for predictive biomarkers such as NECTIN4.

## Indexed commentary on EV-301 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 48
- Podcasts: 44
- YouTube: 40
- X videos: 3
- Bluesky threads: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ev-301-nct03474107

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03474107", "email": "<work email>"}; the inbox owner confirms by the emailed link.